World's first cannabis formulation to help battle insomnia announced

A collaboration to bring the first advanced sleep cannabis formulation has been announced at the Israel-based cannabis conference, CannaTech.

Developer of medical applications for the cannabis plant, CannRx and cannabis start-up investment company iCAN:Israel-Cannabis, announced their cannabis formulation to help sleep, i.can.sleep.

i.can.sleep is the first GMP (Good Manufacturing Practice) pharmaceutical grade cannabis product available to adults who suffer from sleep disorders. The formulation will be launched to a global market following patient trials taking place in 2017. i.can.sleep will use pharmaceutical grade delivery systems to provide a stable, controlled dose.

The formulation uses CannRx’s CannTrap platform, which captures and stabilises cannabinoids produced either by smoking, vaporising or extraction technologies resulting in cannabinoids that are soluble and adequately bioavailable. Since it uses the CannTrap platform, the companies state that i.can.sleep will have a rapid effect with a prolonged duration.

Bill Levine, executive chairman of CannRx Technologies, said: “According to numerous studies, close to 20% of the population in the West in the suffer from insomnia and it is a serious medical problem. Using the breakthrough CannRx technology that can be used to rapidly induce sleep with a prolonged "through the night" therapeutic effect will be of great benefit to this population. We are excited about the opportunity to work together with ICAN team and launch the ican.sleep product.”

Saul Kaye, co-founder of iCAN Israel-Cannabis and CannaTech, said: “As an insomniac myself I am proud to be involved in bringing a next generation cannabis product to the market. Doseable, repeatable cannabis is a reality.”

Jeffrey Friedland, speaker in the cannabis industry and on the CannRx Board of Directors said: “CannRx’s proprietary platform enables the establishment of standard protocols and therapies based upon specific conditions and symptoms - which I believe are critical to the broad acceptance of medical cannabis. “Equally important, CannRx is more than a research and development company, its objective is to generate near-term revenues through the licensing of its technologies in the U.S. to state-licensed medical marijuana businesses, and ican.sleep is our first".